Gilead’s Trodelvy gains EU regulatory momentum, but the first-line TNBC fight is only beginning
Gilead’s Trodelvy may move earlier in metastatic TNBC. The EU signal could reshape first-line ADC use, but adoption questions remain.
Pharma & Biotech
Pharma & Biotech
How Gilead Sciences, Inc. could strengthen its liver disease franchise through Hepcludex commercialization
FDA approval of Hepcludex gives HDV its first U.S. therapy. Find out how this could reshape liver disease treatment and Gilead’s strategy.
Pharma & Biotech
Gilead’s Q1 shows HIV momentum remains powerful, but diversification is still unfinished
Gilead’s HIV engine is roaring again. But acquisition costs and oncology pressure leave investors asking how durable the reset really is.
Pharma & Biotech
Why Gilead’s Arcellx acquisition approval could reshape the multiple myeloma CAR-T race
Gilead has cleared regulatory hurdles for Arcellx. Read why the anito-cel takeover could reshape the multiple myeloma CAR-T market.
Pharma & Biotech
Why Tubulis gives Gilead more than just another antibody-drug conjugate asset
Gilead is acquiring Tubulis to expand its antibody-drug conjugate pipeline. Read what the deal changes for oncology strategy and ADC competition.
Pharma & Biotech
Why Gilead’s Arcellx tender extension matters more for cell therapy execution than for deal timing
Gilead extended its Arcellx tender offer. Read why the move matters for anito-cel, oncology M&A, and cell therapy execution risk.
Pharma & Biotech
Gilead targets durable autoimmune remission with $2.18bn Ouro Medicines acquisition
Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.
Pharma & Biotech
Why Gilead Sciences’ Arcellx acquisition reshapes the competitive dynamics of BCMA CAR T therapy
Gilead Sciences’ acquisition of Arcellx signals a strategic shift in CAR T therapy control and scale. Find out what it changes for multiple myeloma.
Pharma & Biotech
FDA removes CNS limitation for Yescarta, reshaping the regulatory boundary for CAR T therapy in primary CNS lymphoma
Kite Pharma, a subsidiary of Gilead Sciences, has received approval from the U.S. Food and Drug Administration to update the prescribing information for Yescarta axicabtagene ciloleucel by removing the prior limitation of use in patients with relapsed or refractory primary central nervous system lymphoma. The decision follows safety findings from an investigator sponsored Phase 1
Pharma & Biotech
Gilead Sciences acquires RP-3467 from Repare Therapeutics in $30m synthetic lethality deal
Gilead Sciences acquires Repare’s RP-3467 Polθ inhibitor for up to $30M. Find out what this means for BRCA-targeted therapy and synthetic lethality M&A.